HSA vs rHSA — Which Albumin Grade Do You Actually Need?

Human Serum Albumin (HSA) is one of the most widely used proteins in biopharmaceutical manufacturing, cell therapy, diagnostics and research. But "HSA" is not a single product — it is a category that spans four fundamentally different grades, each with different regulatory status, documentation requirements, safety profiles, and appropriate applications.

Choosing the wrong grade costs time, money, and regulatory risk. This guide explains each grade clearly — what it is, who it is for, and when to use it. SeamlessBio supplies all four grades from EU-based sources with full documentation.

The Four Albumin Grades — Overview

Grade 1 — Plasma-Derived HSA

When to choose plasma-derived HSA

• IVD diagnostic kit development where native human albumin matrix is required
• Calibrator and control material in clinical chemistry assays
• Cell culture supplement where defined human protein source is preferred over BSA
• Drug formulation where human albumin excipient is specified but full GMP is not yet required
• Western blot and ELISA blocking where human matrix is relevant

Grade 2 — rHSA Research / Economy Grade

When to choose rHSA Research Grade

• R&D and process development where xeno-free conditions are needed but GMP documentation is not yet required
• Serum-free media formulation development and optimisation
• iPSC feeder-free culture system development
• AAV formulation buffer — 0.001–0.01% to prevent capsid adsorption
• Cost-sensitive research applications where ISO 13485 documentation is not needed

Grade 3 — rHSA ISO 13485 / Near-GMP Grade

ISO 13485 vs GMP — what the difference actually means

This is the question most procurement teams ask — and most suppliers answer poorly.

When to choose rHSA ISO 13485 / Near-GMP Grade

• CAR-T cell therapy process development — pre-Phase I, where GMP documentation is needed but full Eudralex Vol. 4 is not yet required
• iPSC manufacturing for IND-enabling studies
• Vaccine formulation development — pre-clinical and Phase I enabling
• Advanced diagnostics manufacturing where ISO 13485 quality system is specified
• AAV vector formulation — clinical-grade development batches
• Any application where "GMP-like" documentation is required but full pharmaceutical GMP is cost-prohibitive

Grade 4 — rHSA Full GMP Grade

When to choose rHSA GMP Grade

• Phase I/II clinical CAR-T or other ATMP manufacturing — direct EMA/FDA acceptability
• Licensed vaccine product formulation where Ph. Eur. 5.2.12 is mandated
• GMP master cell bank preparation for clinical programmes
• Any application where the regulatory authority has specified full GMP ancillary material

Complete Decision Guide — Which Grade for Which Application

Why EU Supply Chain Matters for Albumin

For European manufacturers submitting to EMA — or for DACH-based CROs and ATMPs working under EU regulations — the origin and supply chain traceability of albumin as an ancillary material is a regulatory question, not just a quality preference.

Frequently Asked Questions

What is the difference between ISO 13485 and pharmaceutical GMP for albumin?

ISO 13485 is a quality management system standard — it certifies that processes are controlled, validated, and traceable. Pharmaceutical GMP (Eudralex Vol. 4 / 21 CFR Part 211) goes further: it requires EMA or FDA facility inspection, batch manufacturing records reviewed by a Qualified Person (QP), and compliance with pharmacopoeial monographs. For most IND-enabling and pre-Phase I applications, ISO 13485 documentation with a risk-based justification is accepted. For Phase I/II ATMP clinical manufacturing, full GMP is required without risk-based justification.

Can plasma-derived HSA be used in CAR-T manufacturing?

For pre-clinical and early process development — yes. For GMP Phase I/II CAR-T manufacturing, plasma-derived HSA requires risk-based justification due to the theoretical blood-borne pathogen risk and donor variability. rHSA ISO 13485 or rHSA GMP Grade eliminates this risk entirely and provides a cleaner regulatory path. EMA/410/01 guidance on ATMPs recommends minimising human- and animal-derived components where possible — rHSA is the preferred option for clinical manufacturing.

Why is rHSA from rice (Oryza sativa) considered premium over yeast-derived?

Rice-expressed rHSA (OsrHSA) produces a protein with post-translational modification profile closer to native plasma-derived HSA — particularly in glycation pattern and fatty acid binding. Yeast-expressed rHSA has slightly different glycation characteristics that can affect drug binding studies. For applications where albumin binding kinetics are measured — drug-serum protein binding assays, DMPK studies, SPR biosensing — OsrHSA is the more accurate surrogate. For cell culture stabilisation and cryopreservation, both perform equivalently.

What documentation does SeamlessBio provide for ISO 13485 Near-GMP rHSA?

Standard documentation includes: CoA with purity, endotoxin, sterility and protein concentration data; Certificate of Origin; MSDS; ISO 13485 certificate; viral safety statement; and process summary document. On request: Ph. Eur. 5.2.12 risk assessment declaration, change control history, extended stability data, and regulatory support letter for IND/CTA submissions.

Related Pages

Technical enquiries, regulatory documentation, batch reservation: info@seamlessbio.de | +49 851 37932226